Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.27 -0.11 (-0.44%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. 
Via MarketBeat
3 Ultra-High-Yield Dividend Stocks to Buy in April
Via The Motley Fool
Topics Energy
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns. 
Via The Motley Fool
The Vanguard S&P 500 ETF Is Sinking, but This Wall Street Analyst Predicts It Will Soar 168% by 2030
Via The Motley Fool
Topics ETFs Economy Stocks
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
From Pfizer Inc.
Via Business Wire
Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification. 
Via Benzinga
Topics ETFs Economy
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events. 
Via Benzinga
Why I Just Bought These 3 Ultra-High-Yield Dividend Stocks
Via The Motley Fool
Topics Energy
What Does the Market Think About Pfizer?
Via Benzinga
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025. 
Via Benzinga
Topics Intellectual Property
Pfizer: Value Play or Past Its Prime?
Via The Motley Fool
10 Best Dividend Stocks Trading Near 52-Week Lows
Blue-chip stocks are established, financially strong, and consistently profitable publicly traded companies. 
Via Talk Markets
Topics Stocks / Equities
What's going on in today's session: S&P500 most active stocks
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed 
Via TheNewswire.com
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. 
Via Benzinga
Why Pfizer Is My Largest Healthcare Position
Via The Motley Fool
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Pfizer Shares Are Down Today: What's Going On?
Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating a claim about the timing of Pfizer's COVID-19 vaccine announcement. 
Via Benzinga
Most active S&P500 stocks in Wednesday's session
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest... 
Via Chartmill
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
Looking for the most active stocks in the S&P500 index on Tuesday?
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'
China is stepping up efforts to reassure U.S. corporate giants like Apple, Pfizer, and Mastercard of its economic potential, with Vice Premier He Lifeng promising a better business environment amid... 
Via Benzinga
Topics World Trade
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Via The Motley Fool
Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers
Via Benzinga
Which Is The Healthiest Investment: Merck Or Pfizer
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.